192例晚期癌症病人美施康定止痛临床观察

目的:评价美施康定治疗晚期癌症病人中、重度癌痛的疗效。 方法:192例中、重度癌痛患者使用美施康定期间 ,观察用药前后及应用不同剂量药物后疼痛的缓解率及不良反应发生情况。 结果 :美施康定治疗后疼痛缓解率为 98.9%。不良反应主要为便秘 (34.4 % ) ,恶心、呕吐 (19.8% )。结论:美施康定对各类癌痛都有良好的镇痛效果 ,其产生的不良反应可以预防并进行有效处理。

An observation of 192 advanced cancer patients treated with MS contin for pain relief

Objective: To observe the response and adverse reactions of MS contin (controlled-release morphine sulfate) to treat severe pain in cancer patients. Method: To sum up the pain relief action and the adverse reactions of 192 patients with moderate severe pain resulting from cancer while using the Ms contin. Result: The rate of pain relief was 98.9%,and the main adverse reactions were constipation,nausea and vomiting. Conclusions: The ratio of pain relief in cancer pationts of this group is 98.9%,which suggests MS contin has significant effect on various types of cancer and it accords with the guide principle of three-step cancer pain relief. We think that MS contin has steady blood-drug concentration in vivo,has a long lasting effect,is easy to use,and the side effects can be prevented and dealt with effectively. MS contin is the ideal drug for relieving mediate to severe cancer pain in clinical treatment.